Gsk (GSK) Beginning Cash Balance (2009 - 2026)
Gsk (GSK) posted quarterly Beginning Cash Balance of $4.3 billion for Q1 2026, up 0.88% year-over-year from $4.3 billion in Q1 2025, and down 4.48% quarter-over-quarter from $4.5 billion in Q4 2025.
Gsk (GSK) Beginning Cash Balance (2009 - 2026) Analysis & Trends
Gsk's Beginning Cash Balance history runs 18 years deep, the most recent figure standing at $4.3 billion for Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.32 Bn |
| Mar 31, 2026 | 4.32 Bn |
| Dec 31, 2025 | 4.53 Bn |
| Dec 31, 2025 | 4.53 Bn |
| Mar 31, 2025 | 4.29 Bn |
| Mar 31, 2025 | 4.29 Bn |
| Dec 31, 2024 | 3.67 Bn |
| Dec 31, 2024 | 3.67 Bn |
| Mar 31, 2024 | 3.63 Bn |
| Mar 31, 2024 | 3.63 Bn |
| Dec 31, 2023 | 4.25 Bn |
| Dec 31, 2023 | 4.25 Bn |
| Mar 31, 2023 | 4.16 Bn |
| Mar 31, 2023 | 4.16 Bn |
| Dec 31, 2022 | 4.48 Bn |
| Dec 31, 2022 | 4.48 Bn |
| Mar 31, 2022 | 5.12 Bn |
| Mar 31, 2022 | 5.12 Bn |
| Dec 31, 2021 | 7.09 Bn |
| Dec 31, 2021 | 7.09 Bn |